RBC Capital analyst Frank Morgan maintained a Buy rating on Surgery Partners (NASDAQ:SGRY) Inc on Monday, setting a price target of $36, which is approximately 30.43% above the present share price of $27.6.
Morgan expects Surgery Partners Inc to post earnings per share (EPS) of -$1.46 for the first quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Surgery Partners, with an average price target of $35.
The analysts price targets range from a high of $36 to a low of $34.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $496.1 million and a net profit of $55 million. The company's market cap is $1.46 billion.
According to TipRanks.com, RBC Capital analyst Frank Morgan is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.0% and a 68.31% success rate.
Surgery Partners, Inc. is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services, Ancillary Services, and Optical Services. The Surgical Facility Services segment consists of the operation of ambulatory surgery centers and surgical hospitals, including anesthesia services of the company. The Ancillary Services segment operates a diagnostic laboratory and multi-specialty physician practices. The Optical Services segment involves an optical laboratory and an optical products group purchasing organization. The company was founded in 2004 and is headquartered in Brentwood, TN.